메뉴 건너뛰기




Volumn 13, Issue 5, 2008, Pages 384-394

Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer

Author keywords

Adverse events; Aromatase inhibitor; Breast cancer; Joint symptom; Lipid profile; Osteoporosis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

EID: 54849424382     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0828-5     Document Type: Review
Times cited : (18)

References (53)
  • 1
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • Early Breast Cancer Trialist' Group
    • Early Breast Cancer Trialist' Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 2
    • 11444251764 scopus 로고    scopus 로고
    • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    • A. Howell J. Cuzick M. Baum 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62
    • (2005) Lancet , vol.365 , pp. 60-62
    • Howell, A.1    Cuzick, J.2    Baum, M.3
  • 3
    • 33746408229 scopus 로고    scopus 로고
    • Comprehensive sideeffect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial
    • A. Buzdar A. Howell J. Cuzick 2006 Comprehensive sideeffect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633 643
    • (2006) Lancet Oncol , vol.7 , pp. 633-643
    • Buzdar, A.1    Howell, A.2    Cuzick, J.3
  • 4
    • 33947510501 scopus 로고    scopus 로고
    • Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98
    • A.S. Coates A. Keshaviah B. Thurlimann 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492
    • (2007) J Clin Oncol , vol.25 , pp. 486-492
    • Coates, A.S.1    Keshaviah, A.2    Thurlimann, B.3
  • 5
    • 42949164467 scopus 로고    scopus 로고
    • Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial
    • D. Crivellari Z. Sun A.S. Coates 2008 Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial J Clin Oncol 26 1972 1979
    • (2008) J Clin Oncol , vol.26 , pp. 1972-1979
    • Crivellari, D.1    Sun, Z.2    Coates, A.S.3
  • 6
    • 10744223655 scopus 로고    scopus 로고
    • A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer
    • R.C. Coombes E. Hall L.J. Gibson 2004 A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092
    • (2004) N Engl J Med , vol.350 , pp. 1081-1092
    • Coombes, R.C.1    Hall, E.2    Gibson, L.J.3
  • 7
    • 33846545851 scopus 로고    scopus 로고
    • Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial
    • R.C. Coombes L.S. Kilburn C.F. Snowdon 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570
    • (2007) Lancet , vol.369 , pp. 559-570
    • Coombes, R.C.1    Kilburn, L.S.2    Snowdon, C.F.3
  • 8
    • 23444446523 scopus 로고    scopus 로고
    • Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial
    • R. Jakesz W. Jonat M. Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462
    • (2005) Lancet , vol.366 , pp. 455-462
    • Jakesz, R.1    Jonat, W.2    Gnant, M.3
  • 9
    • 33745613829 scopus 로고    scopus 로고
    • Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial
    • Suppl7
    • F. Boccardo A. Rubagotti P. Guglielmini 2006 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial Ann Oncol 17 Suppl7 vii
    • (2006) Ann Oncol , vol.17
    • Boccardo, F.1    Rubagotti, A.2    Guglielmini, P.3
  • 10
    • 24744450378 scopus 로고    scopus 로고
    • Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17
    • P.E. Goss J.N. Ingle S. Martino 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 1262 1271
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1262-1271
    • Goss, P.E.1    Ingle, J.N.2    Martino, S.3
  • 11
    • 42949112558 scopus 로고    scopus 로고
    • Late extended adjuvant treatment with letrozole improves outcome in women with earlystage breast cancer who complete 5 years of tamoxifen
    • P.E. Goss J.N. Ingle J.L. Pater 2008 Late extended adjuvant treatment with letrozole improves outcome in women with earlystage breast cancer who complete 5 years of tamoxifen J Clin Oncol 26 1948 1955
    • (2008) J Clin Oncol , vol.26 , pp. 1948-1955
    • Goss, P.E.1    Ingle, J.N.2    Pater, J.L.3
  • 12
    • 38449107897 scopus 로고    scopus 로고
    • Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
    • R. Jakesz R. Greil M. Gnant 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a J Natl Cancer Inst 99 1845 1853
    • (2007) J Natl Cancer Inst , vol.99 , pp. 1845-1853
    • Jakesz, R.1    Greil, R.2    Gnant, M.3
  • 13
    • 42949104549 scopus 로고    scopus 로고
    • Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Sur gical Adjuvant Breast and Bowel Project B-33 trial
    • E.P. Mamounas J.H. Jeong D.L. Wickerham 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Sur gical Adjuvant Breast and Bowel Project B-33 trial J Clin Oncol 26 1965 1971
    • (2008) J Clin Oncol , vol.26 , pp. 1965-1971
    • Mamounas, E.P.1    Jeong, J.H.2    Wickerham, D.L.3
  • 14
    • 85047681459 scopus 로고    scopus 로고
    • 17 Beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha
    • M. Saika D. Inoue S. Kido 2001 17 Beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha Endocrinology 142 2205 2212
    • (2001) Endocrinology , vol.142 , pp. 2205-2212
    • Saika, M.1    Inoue, D.2    Kido, S.3
  • 15
    • 0034608813 scopus 로고    scopus 로고
    • Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression
    • N.K. Shevde A.C. Bendixen K.M. Dienger 2000 Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression Proc Natl Acad Sci U S A 97 7829 7834
    • (2000) Proc Natl Acad Sci U S a , vol.97 , pp. 7829-7834
    • Shevde, N.K.1    Bendixen, A.C.2    Dienger, K.M.3
  • 16
    • 0035831020 scopus 로고    scopus 로고
    • Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity
    • S. Kousteni T. Bellido L.I. Plotkin 2003 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity Cell 104 719 730
    • (2003) Cell , vol.104 , pp. 719-730
    • Kousteni, S.1    Bellido, T.2    Plotkin, L.I.3
  • 17
    • 0034719619 scopus 로고    scopus 로고
    • Osteoporosis prevention, diagnosis, and therapy
    • Anonymous
    • Anonymous (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement. 17:1-45
    • (2000) NIH Consensus Statement , vol.17 , pp. 1-45
  • 18
    • 41949094767 scopus 로고    scopus 로고
    • Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230
    • R. Eastell J.E. Adams R.E. Coleman 2008 Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230 J Clin Oncol 26 1051 1057
    • (2008) J Clin Oncol , vol.26 , pp. 1051-1057
    • Eastell, R.1    Adams, J.E.2    Coleman, R.E.3
  • 19
    • 37449028688 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
    • J.F. Forbes J. Cuzick A. Buzdar 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53
    • (2008) Lancet Oncol , vol.9 , pp. 45-53
    • Forbes, J.F.1    Cuzick, J.2    Buzdar, A.3
  • 20
    • 52749089132 scopus 로고    scopus 로고
    • Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial
    • on behalf of ATAC Trialist' Group (May suppl; abstr act 587)
    • Coleman RE on behalf of ATAC Trialist' Group (2008) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. J Clin Oncol 26: (May suppl; abstr act 587)
    • (2008) J Clin Oncol , vol.26
    • Coleman, R.E.1
  • 21
    • 33846545488 scopus 로고    scopus 로고
    • Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study
    • R.E. Coleman L.M. Banks S.I. Girgis 2007 Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 119 127
    • (2007) Lancet Oncol , vol.8 , pp. 119-127
    • Coleman, R.E.1    Banks, L.M.2    Girgis, S.I.3
  • 22
    • 33747058527 scopus 로고    scopus 로고
    • Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17
    • E.A. Perez R.G. Josse K.I. Pritchard 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 24 3629 3635
    • (2006) J Clin Oncol , vol.24 , pp. 3629-3635
    • Perez, E.A.1    Josse, R.G.2    Pritchard, K.I.3
  • 23
    • 24644434439 scopus 로고    scopus 로고
    • Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer
    • P.E. Lonning J. Geisler L.E. Krag 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer J Clin Oncol 23 5126 5137
    • (2005) J Clin Oncol , vol.23 , pp. 5126-5137
    • Lonning, P.E.1    Geisler, J.2    Krag, L.E.3
  • 24
    • 33750522464 scopus 로고    scopus 로고
    • Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study
    • J. Geisler P.E. Lonning L.E. Krag 2006 Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study Eur J Cancer 42 2968 2975
    • (2006) Eur J Cancer , vol.42 , pp. 2968-2975
    • Geisler, J.1    Lonning, P.E.2    Krag, L.E.3
  • 25
    • 0642342669 scopus 로고    scopus 로고
    • American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
    • B.E. Hillner J.N. Ingle R.T. Chlebowski 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 4042 4057
    • (2003) J Clin Oncol , vol.21 , pp. 4042-4057
    • Hillner, B.E.1    Ingle, J.N.2    Chlebowski, R.T.3
  • 27
    • 34548537700 scopus 로고    scopus 로고
    • Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer
    • K.D. Crew H. Greenlee J. Capodice 2007 Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer J Clin Oncol 25 3877 3883
    • (2007) J Clin Oncol , vol.25 , pp. 3877-3883
    • Crew, K.D.1    Greenlee, H.2    Capodice, J.3
  • 28
    • 34948816221 scopus 로고    scopus 로고
    • Clinical features of joint symptoms observed in the 'Arimidex' Tamoxifen, Alone or in Combination (ATAC) trial
    • A. Buzdar 2006 Clinical features of joint symptoms observed in the 'Arimidex' Tamoxifen, Alone or in Combination (ATAC) trial J Clin Oncol 2006 Annual Meeting Proceedings Part I 124 551
    • (2006) J Clin Oncol 2006 Annual Meeting Proceedings Part I , vol.124 , pp. 551
    • Buzdar, A.1
  • 29
    • 34250866267 scopus 로고    scopus 로고
    • Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: Associated tenosynovial changes on magnetic resonance imaging
    • L. Morales S. Pans R. Paridaens 2007 Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging Breast Cancer Res Treat 104 87 91
    • (2007) Breast Cancer Res Treat , vol.104 , pp. 87-91
    • Morales, L.1    Pans, S.2    Paridaens, R.3
  • 30
    • 49249091589 scopus 로고    scopus 로고
    • Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome
    • L. Morales S. Pans K. Verschueren 2008 Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome J Clin Oncol 26 3147 3152
    • (2008) J Clin Oncol , vol.26 , pp. 3147-3152
    • Morales, L.1    Pans, S.2    Verschueren, K.3
  • 31
    • 33749533784 scopus 로고    scopus 로고
    • Estrogen receptorbeta is the predominant estrogen receptor subtype in normal human synovia
    • W. Dietrich A. Haitel G. Holzer 2006 Estrogen receptorbeta is the predominant estrogen receptor subtype in normal human synovia J Soc Gynecol Investig 13 512 517
    • (2006) J Soc Gynecol Investig , vol.13 , pp. 512-517
    • Dietrich, W.1    Haitel, A.2    Holzer, G.3
  • 32
    • 33244472357 scopus 로고    scopus 로고
    • Locally produced estrogen promotes fetal rat metatarsal bone growth; An effect mediated through increased chondrocyte proliferation and decreased apoptosis
    • A.S. Chagin D. Chrysis M. Takigawa 2006 Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis J Endocrinol 188 193 203
    • (2006) J Endocrinol , vol.188 , pp. 193-203
    • Chagin, A.S.1    Chrysis, D.2    Takigawa, M.3
  • 33
    • 8444222790 scopus 로고    scopus 로고
    • Ovariectomized rats as a model of postmenopausal osteoarthritis: Validation and application
    • P. Hoegh-Andersen L.B. Tanko T.L. Andersen 2004 Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application Arthritis Res Ther 6 R169 180
    • (2004) Arthritis Res Ther , vol.6 , pp. 169-180
    • Hoegh-Andersen, P.1    Tanko, L.B.2    Andersen, T.L.3
  • 34
    • 0027971724 scopus 로고
    • The menopausal transition: A dynamic approach to the pathogenesis of neurovegetative complaints
    • F. Pansini P. Albertazzi G. Bonaccorsi 1994 The menopausal transition: a dynamic approach to the pathogenesis of neurovegetative complaints Eur J Obstet Gynecol Reprod Biol 57 103 109
    • (1994) Eur J Obstet Gynecol Reprod Biol , vol.57 , pp. 103-109
    • Pansini, F.1    Albertazzi, P.2    Bonaccorsi, G.3
  • 35
    • 48649092861 scopus 로고    scopus 로고
    • Tolerance of adjuvant letrozole outside of clinical trials
    • Fontaine C, Meulemans A, Huizing M, et al. (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast
    • (2008) Breast
    • Fontaine, C.1    Meulemans, A.2    Huizing, M.3
  • 36
    • 0036829442 scopus 로고    scopus 로고
    • Effects of anastrozole on lipid metabolism compared with tamoxifen in rats
    • Y. Hozumi Y. Hakamata H. Sasanuma 2002 Effects of anastrozole on lipid metabolism compared with tamoxifen in rats Breast Cancer Res Treat 76 131 136
    • (2002) Breast Cancer Res Treat , vol.76 , pp. 131-136
    • Hozumi, Y.1    Hakamata, Y.2    Sasanuma, H.3
  • 37
    • 4444273111 scopus 로고    scopus 로고
    • Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats
    • P.E. Goss S. Qi A.M. Cheung 2004 Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats Clin Cancer Res 10 5717 5723
    • (2004) Clin Cancer Res , vol.10 , pp. 5717-5723
    • Goss, P.E.1    Qi, S.2    Cheung, A.M.3
  • 38
    • 1542346356 scopus 로고    scopus 로고
    • The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats
    • P.E. Goss S. Qi R.G. Josse 2004 The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats Bone 34 384 392
    • (2004) Bone , vol.34 , pp. 384-392
    • Goss, P.E.1    Qi, S.2    Josse, R.G.3
  • 39
    • 25644458142 scopus 로고    scopus 로고
    • Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the IMPACT trial
    • S. Banerjee I.E. Smith L. Folkerd 2005 Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the IMPACT trial Ann Oncol 16 1632 168
    • (2005) Ann Oncol , vol.16 , pp. 1632-168
    • Banerjee, S.1    Smith, I.E.2    Folkerd, L.3
  • 40
    • 17144430927 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer
    • S. Sawada K. Sato M. Kusuhara 2005 Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer Acta Oncol 44 134 141
    • (2005) Acta Oncol , vol.44 , pp. 134-141
    • Sawada, S.1    Sato, K.2    Kusuhara, M.3
  • 41
    • 0034885923 scopus 로고    scopus 로고
    • Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
    • M.S. Elisaf E.T. Bairaktari C. Nicolaides 2001 Effect of letrozole on the lipid profile in postmenopausal women with breast cancer Eur J Cancer 37 1510 1513
    • (2001) Eur J Cancer , vol.37 , pp. 1510-1513
    • Elisaf, M.S.1    Bairaktari, E.T.2    Nicolaides, C.3
  • 42
    • 20044380552 scopus 로고    scopus 로고
    • The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
    • K.M. Wasan P.E. Goss P.H. Pritchard 2005 The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Ann Oncol 16 707 715
    • (2005) Ann Oncol , vol.16 , pp. 707-715
    • Wasan, K.M.1    Goss, P.E.2    Pritchard, P.H.3
  • 43
    • 10744233292 scopus 로고    scopus 로고
    • The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC Trial 10951, "randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients"
    • G. Atalay L. Dirix L. Biganzoli 2004 The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, "Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients" Ann Oncol 15 211 217
    • (2004) Ann Oncol , vol.15 , pp. 211-217
    • Atalay, G.1    Dirix, L.2    Biganzoli, L.3
  • 44
    • 24044527243 scopus 로고    scopus 로고
    • The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study
    • C. Markopoulos A. Polychronis V. Zobolas 2005 The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study Breast Cancer Res Treat 93 61 66
    • (2005) Breast Cancer Res Treat , vol.93 , pp. 61-66
    • Markopoulos, C.1    Polychronis, A.2    Zobolas, V.3
  • 45
    • 29544433211 scopus 로고    scopus 로고
    • A Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • Breast International Group 1-98 Collaborative Group
    • Breast International Group 1-98 Collaborative Group 2005 A Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer New Engl J Med 353 2747 2757
    • (2005) New Engl J Med , vol.353 , pp. 2747-2757
  • 46
    • 29544433211 scopus 로고    scopus 로고
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • B. Thurlimann A. Keshaviah A.S. Coates 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757
    • (2005) N Engl J Med , vol.353 , pp. 2747-2757
    • Thurlimann, B.1    Keshaviah, A.2    Coates, A.S.3
  • 47
    • 36048965807 scopus 로고    scopus 로고
    • Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer
    • C.M. Bender S.M. Sereika A.M. Brufsky 2007 Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer Menopause 14 995 998
    • (2007) Menopause , vol.14 , pp. 995-998
    • Bender, C.M.1    Sereika, S.M.2    Brufsky, A.M.3
  • 48
    • 33644775724 scopus 로고    scopus 로고
    • Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology
    • B. Gerber A. Krause T. Reimer 2006 Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology Clin Cancer Res 12 1245 1250
    • (2006) Clin Cancer Res , vol.12 , pp. 1245-1250
    • Gerber, B.1    Krause, A.2    Reimer, T.3
  • 49
    • 16544365765 scopus 로고    scopus 로고
    • Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
    • L. Fallowfield D. Cella J. Cuzick 2004 Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial J Clin Oncol 22 4261 4271
    • (2004) J Clin Oncol , vol.22 , pp. 4261-4271
    • Fallowfield, L.1    Cella, D.2    Cuzick, J.3
  • 50
    • 33750715386 scopus 로고    scopus 로고
    • Quality of life of postmenopausal women in the ATAC ("Arimidex" , Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer
    • D. Cella L. Fallowfield P. Barker 2006 Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 273 284
    • (2006) Breast Cancer Res Treat , vol.100 , pp. 273-284
    • Cella, D.1    Fallowfield, L.2    Barker, P.3
  • 51
    • 33644896808 scopus 로고    scopus 로고
    • Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
    • L.J. Fallowfield J.M. Bliss L.S. Porter 2006 Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer J Clin Oncol 24 910 917
    • (2006) J Clin Oncol , vol.24 , pp. 910-917
    • Fallowfield, L.J.1    Bliss, J.M.2    Porter, L.S.3
  • 52
    • 27244436756 scopus 로고    scopus 로고
    • Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
    • T.J. Whelan P.E. Goss J.N. Ingle 2005 Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women J Clin Oncol 23 6931 6940
    • (2005) J Clin Oncol , vol.23 , pp. 6931-6940
    • Whelan, T.J.1    Goss, P.E.2    Ingle, J.N.3
  • 53
    • 43249123925 scopus 로고    scopus 로고
    • Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
    • R. Thomas M. Williams C. Marshall 2008 Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women Br J Cancer 98 1494 1499
    • (2008) Br J Cancer , vol.98 , pp. 1494-1499
    • Thomas, R.1    Williams, M.2    Marshall, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.